Literature DB >> 1679660

Calcium antagonists post-infarction: the significance of experimental studies on potentially lethal early ischemic ventricular arrhythmias.

L H Opie.   

Abstract

The DAVIT-II trial has shown that the verapamil type of calcium antagonist can beneficially be used in post-infarct patients. A recent re-analysis suggests that verapamil may also prevent post-infarct sudden death. There are good theoretical reasons to suppose that calcium antagonists should help prevent ventricular fibrillation. If calcium antagonist agents could be found which have negligible negative inotropic effects, such drugs might be ideal for further testing in the post-infarct phase.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1679660     DOI: 10.1007/bf03029739

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  26 in total

1.  Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies.

Authors:  S Yusuf; P Held; C Furberg
Journal:  Am J Cardiol       Date:  1991-06-01       Impact factor: 2.778

2.  Calcium channel blockers and congestive heart failure.

Authors:  G S Francis
Journal:  Circulation       Date:  1991-01       Impact factor: 29.690

3.  What is the solution to sudden cardiac death: calcium modulation or arrhythmia clinics?

Authors:  W T Clusin
Journal:  Cardiovasc Drugs Ther       Date:  1987-12       Impact factor: 3.727

Review 4.  A potential role of calcium ions in early ischemic and reperfusion arrhythmias.

Authors:  L H Opie; W A Coetzee; S C Dennis; F T Thandroyen
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

5.  Long-term clinical, hemodynamic, angiographic, and neurohumoral responses to vasodilation with felodipine in patients with chronic congestive heart failure.

Authors:  E Kassis; O Amtorp
Journal:  J Cardiovasc Pharmacol       Date:  1990-03       Impact factor: 3.105

6.  Effects of components of ischemia and metabolic inhibition on delayed afterdepolarizations in guinea pig papillary muscle.

Authors:  W A Coetzee; L H Opie
Journal:  Circ Res       Date:  1987-08       Impact factor: 17.367

7.  Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group.

Authors:  R E Goldstein; S J Boccuzzi; D Cruess; S Nattel
Journal:  Circulation       Date:  1991-01       Impact factor: 29.690

8.  Effects of diltiazem on conduction of premature impulses during acute myocardial ischemia and reperfusion.

Authors:  T Fujimoto; T Peter; H Hamamoto; W J Mandel
Journal:  Am J Cardiol       Date:  1981-11       Impact factor: 2.778

9.  Relation between beta-adrenergic blocker use, various correlates of left ventricular function and the chance of developing congestive heart failure. The Multicenter Diltiazem Post-Infarction Research Group.

Authors:  E Lichstein; W D Hager; J J Gregory; J L Fleiss; L M Rolnitzky; J T Bigger
Journal:  J Am Coll Cardiol       Date:  1990-11       Impact factor: 24.094

10.  Magnitude and time course of extracellular potassium inhomogeneities during acute ischemia in pigs. Effect of verapamil.

Authors:  T A Johnson; C L Engle; L M Boyd; G G Koch; M Gwinn; L S Gettes
Journal:  Circulation       Date:  1991-02       Impact factor: 29.690

View more
  2 in total

1.  Effect of verapamil on arrhythmias and heart rate during 16 months following an acute myocardial infarction. The Danish Study Group on Verapamil in Myocardial Infarction.

Authors:  M Vaage-Nilsen; V Rasmussen; J F Hansen; L Hagerup; M B Sørensen; O Pedersen-Bjergaard; K Mellemgaard; N H Holländer; I Nielsen; B M Sigurd
Journal:  Cardiovasc Drugs Ther       Date:  1994-02       Impact factor: 3.727

2.  Secondary prevention with calcium antagonists after acute myocardial infarction.

Authors:  J F Hansen
Journal:  Drugs       Date:  1992       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.